Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)

Condition(s) studied

Investigational drug(s) / intervention(s)

Tolerance and adherence to oral antibiotics in patients managed for BJI: Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery. The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire). Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3. Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.

Study summary

Bone and joint infections (BJI) are most often bacterial infections that can occur after surgery or de novo. They are rarely fatal in the short term, but are associated with significant morbidity, impaired quality of life and significant costs. Treatment of BJI is based on antibiotic therapy, often combined with surgery. Antibiotic therapy, at high doses, lasts a minimum of 6 weeks. It can be responsible for severe adverse effects. These characteristics (prolonged duration, multiple daily doses, and adverse effects) are known to negatively affect treatment adherence in general.

Eligibility

Primary outcome measure(s)

• Percentage of doses taken at 6 weeks — At 6 weeks after surgery
  Ratio of the number of doses taken over the theoretical number of doses to be taken over the period
• Percentage of doses taken at 3 months — at 3 months after surgery
  Ratio of the number of doses taken over the theoretical number of doses to be taken over the period

Trial sites (1)

More Hospices Civils de Lyon trials in France

Other trials for the same condition